Eagerly Awaited Expanded Xtandi Label Should Accelerate Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivation had already expanded its enzalutamide sales force to complement partner Astellas’ team ahead of getting a new indication for the earlier, pre-chemotherapy prostate cancer setting. The expanded label now paves the way for reps to drop in on more urologists.